Canaccord analyst Whitney Ijem raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $114 from $105 and keeps a Buy rating on the shares. The firm said following a relatively uneventful 3Q25 report, the company announced that the PDUFA data for aHO has been extended by 3months to March 20, 2026 from December 20, 2025 previously. Canaccord remains confident that the aHO indication will be approved by March 20, 206 given setmelanotide’s strong efficacy and safety profile, and they agree with the company’s sentiment that the extension will only give them time to be even more prepared for launch.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Positive Outlook for Rhythm Pharmaceuticals Despite FDA Review Delay and Financial Shortfall
- Rhythm Pharmaceuticals Faces FDA Review Extension
- Rhythm announces FDA extension of review period for IMCIVREE
- Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Optimism
- Rhythm Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer